Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed... see more

TSX:PRN - Post Discussion

Profound Medical Corp > Daily Buy/Sell Adviser
View:
Post by retiredcf on Jul 24, 2020 6:38am

Daily Buy/Sell Adviser

Unable to post the entire article so here's the link. PRN is the second company featured. GLTA

https://www.adviceforinvestors.com/news/canadian-stocks/2-best-healthcare-stocks-to-buy-now/#gsc.tab=0

2 best healthcare stocks to buy now

A manufacturer of higher-value, higher-margin edible, vape and beverage products and a provider of incision-free therapies for the treatment of prostate cancer are “strong buys”.

Before this year’s stock market correction, the cannabis industry suffered a "bloodletting" in late 2019 due to poor financial results and uncertainty about when the next phase of product introduction would start, Raymond James Financial analyst Rahul Sarugaser had commented then. Since the dust has settled, however, he can think of at least one pot stock that investors may want to pick up for themselves.

Residing in Toronto, Mr. Sarugaser is a managing director and equity analyst at Raymond James responsible for medical technologies research. Prior to joining the firm in 2019, he worked as an equities analyst at Paradigm Capital specializing in healthcare and biotechnology coverage. The analyst has spent years working in areas where finance and science are tied, fittingly, considering his scientific bona fides, which include a master’s degree and doctorate in biomedical engineering from the University of Toronto. He also holds an MBA from the University of Oxford.

 
Comment by MUGMODs on Jul 24, 2020 9:11am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities